Cell Therapy And Technology, S.a. De C.v. Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2005
NCT02161952
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

pirfenidone (esbriet) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Kidney Diseases (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1